An Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
| Status: | Not yet recruiting |
|---|---|
| Conditions: | Neurology, Neurology |
| Therapuetic Areas: | Neurology |
| Healthy: | No |
| Age Range: | 18 - Any |
| Updated: | 4/3/2019 |
| Start Date: | July 2019 |
| End Date: | March 2021 |
| Contact: | Momenta General Queries |
| Email: | ClinicalTrialInfo@momentapharma.com |
| Phone: | +1 617-491-9700 |
An Open-label Extension Study of MOM-M281-004 to Evaluate the Safety, Tolerability, and Efficacy of M281 Administered to Patients With Generalized Myasthenia Gravis
The purpose of this study is to evaluate the long-term safety and tolerability of M281 in
participants with generalized myasthenia gravis (gMG)
participants with generalized myasthenia gravis (gMG)
Participants must be ≥18 years of age with a documented history of Generalized Myasthenia
Gravis (gMG) and clinical signs/symptoms of gMG, not pregnant or breastfeeding, previously
participated in the MOM-281-004 study, had no major eligibility deviations or other major
protocol deviations or not met any of the stopping criteria or discontinued study drug in
the MOM-M281-004 study for any reason other than the need for rescue therapy as specified
in the MOM-M281-004 study.
Additional, more specific criteria are defined in the protocol.
We found this trial at
7
sites
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials
Click here to add this to my saved trials